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Abstract Targeted treatments are needed for advanced adult-
type granulosa cell tumors (AGCTs). We set out to assess
tumor tissue and circulating levels of TNF-related apoptosis-
inducing ligand (TRAIL), a promising anti-cancer cytokine, in
patients affected by AGCT. We analyzed tissue expression of
TRAIL in 127 AGCTs using immunohistochemistry or RT-
PCR. Soluble TRAIL was measured bymeans of ELISA from
141 AGCT patient serum samples, as well as the conditioned
media of 15 AGCT patient-derived primary cell cultures, and
the KGN cell line. Tissue and serum TRAIL levels were ana-
lyzed in relationship with clinical parameters, and serum es-
tradiol, FSH, and LH levels. We found that AGCT samples
expressed TRAIL mRNA and protein at levels comparable to
normal granulosa cells. AGCT cells did not release soluble
TRAIL. TRAIL protein levels were decreased in tumors over
10 cm in diameter (p=0.04). Consistently, circulating TRAIL
levels correlated negatively to tumor dimension (p=0.01).
Circulating TRAIL levels negatively associated with serum
estradiol levels. In multiple regression analysis, tumor size
was an independent factor contributing to the decreased levels
of soluble TRAIL in AGCT patients. AGCTs associate with
significantly decreased tumor tissue and serum TRAIL levels
in patients with a large tumor mass. These findings encourage
further study of agonistic TRAIL treatments in patients with
advanced or recurrent AGCT.
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Background
Ovarian granulosa cell tumors (GCTs) are hormonally active
sex cord-stromal tumors, which represent 5 % of all ovarian
malignancies. Adult-type GCTs (AGCTs) are usually diag-
nosed at an early stage, but recurrences occur in 20–30 % of
the patients after a median time of 4–7 years [1, 2]. These
recurrences are associated with a high mortality, and early
detection and complete tumor removal are key elements in
the treatment of recurrent AGCT [3, 4]. Adjuvant treatments
have limited proven efficacy on recurrent or advanced-stage
AGCT [5], and biologically targeted treatment modalities are
lacking.
Clinical trials show a promising activity of the TNF-related
apoptosis-inducing ligand (TRAIL) cytokine and of agonistic
anti-TRAIL receptor antibody against a variety of solid tumors
[6–11]. TRAIL is expressed by different cell types belonging
predominantly to the immune system [12] either as type II
transmembrane homo-trimer or as a soluble protein, detectable
in circulation under physiological conditions [12]. The best
Electronic supplementary material The online version of this article
(doi:10.1007/s13277-016-5042-x) contains supplementary material,
which is available to authorized users.
* Anniina Färkkilä
anniina.farkkila@helsinki.fi
1 Deparment of Obstetrics and Gynecology, University of Helsinki and
Helsinki University Hospital, 00014 Helsinki, Finland
2 Children’s Hospital, Pediatric Research Center, University of
Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland
3 Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”,
Trieste, Italy
4 Department of Morphology, Surgery, Experimental Medicine and
LTTA Centre, University of Ferrara, Ferrara, Italy
5 Department of Pediatrics, Washington University School of
Medicine, St Louis Children’s Hospital, St Louis, MO 63110, USA
Tumor Biol. (2016) 37:11909–11916
DOI 10.1007/s13277-016-5042-x
characterized role of TRAIL is to act as an anti-cancer molecule
[13, 14]; this is also clearly demonstrated in TRAIL knockout
animal studies showing that lack of TRAIL promotes chronic
inflammation, tumorigenesis, and metastasis [15, 16]. We and
others have previously demonstrated that adult ovaries
expressed TRAIL and its receptors TRAIL-R2, TRAIL-R3,
and TRAIL-R4 in granulosa cells of small and larger antral
follicles [17, 18]. Moreover, TRAIL pathway components are
active in AGCTs, and recombinant human TRAIL induces ap-
optosis in AGCT cells in vitro [17–21]. In addition, clinical
response of 23% reduction inmeasurable disease was observed
in a patient with advanced AGCT, treated with 4 mg/kg of an
agonistic anti-TRAIL-receptor-2 antibody [11].
AGCT has a distinct molecular background; most AGCTs
harbor a single somatic point mutation in a gene encoding for
transcription factor FOXL2 [22, 23]. Still, the pathogenesis of
AGCTs remains largely unraveled. Originating from the hor-
monally active granulosa cells, AGCTs produce, e.g., estradiol,
anti-Müllerian hormone, and inhibins, and express receptors
for follicle-stimulating hormone (FSH) and luteinizing hor-
mone (LH) (reviewed in [24]). Recently, estradiol was found
to negatively regulate TRAIL expression in leukocytes [25].
On these bases, we evaluated the tumor tissue expression
and the circulating levels of TRAIL in patients affected by
AGCT, and evaluated the levels in relation to clinical and
hormonal parameters.
Patients and methods
Real-time PCR and primary cell cultures
Total RNAwas extracted from 46 primary tumor samples, and
one human granulosa-luteal cell sample, three primary AGCT
cell samples, and the KGN cell line and using the Qiagen
RNeasy Plus mini kit (Qiagen, Hilden, Germany) according to
the supplier’s instructions, and as previously described [26].
Once verified the quality of RNA preparation by agarose gel,
total RNA was transcribed into cDNA, using the QuantiTect®
Reverse Transcription kit (Qiagen). TRAIL gene expression was
analyzed using the SYBR Green-based real-time quantitative
polymerase chain reaction (RT qPCR) detection method with
SA Biosciences RT2 Real-TimeTM Gene expression assays,
which include specific validated primer sets and PCR master
mix (SABiosciences, Frederick, MD). The samples were run in
triplicate using the real time thermal analyzer Rotor-GeneTM
6000 (Corbett, Cambridge, UK), or with ABI Prism 7900HT
(Thermo Fisher Scientific, MA, USA) as previously described
[21, 26]. Expression values were normalized to the housekeeping
gene POLR2A or Cyclophilin amplified in the same sample and
expressed in arbitrary units as described [27].
During 2007–2010, we obtained ten primary and five recur-
rent AGCTs for primary cell cultures, whichwere established as
described [21]. In brief, the fresh tumor tissue wasmechanically
minced and treated with 0.5 % collagenase (Sigma-Aldrich
Corp., St. Louis, MO), filtered through a 140-mm filter mesh,
and the single cells were plated in the DMEM/F12 containing
10% fetal bovine serum. The cells were cultured in 5%CO2 at
+37 °C temperature. All the primary AGCTcells and the KGN
cells harbored the c.402C->G (C134W) mutation in FOXL2
[22]. KGN cells were cultured as described [28]. Cell culture
supernatant was collected after 2–5 days depending on cell
confluence and analyzed for the release of soluble TRAIL by
ELISA (R&D Systems), according to instructions and as pre-
viously described [13].
Immunofluorescence
Primary AGCT cells were plated on 4-well chamber glasses on
day 6 after primary culture establishment. On day 10, the cells
were fixedwith 4%PFA, permeabilized with 0.1%PBS-Triton-
X, blocked with 1 % BSA, and stained with primary antibodies
for FOXL2 (sc-25825, Santa-Cruz Biotechnologies, TX, USA)
and TRAIL (sc-1891, Santa-Cruz) in 1:100 dilution at +4 °C o/n.
Secondary antibody only was utilized as a control (data not
shown). Secondary antibody in 1:500 dilution with Alexa fluor
488 (GFP) conjugate was incubated for 1 h at room temperature,
and the nuclei were counterstained with DAPI.
Immunohistochemistry
An AGCT tissue microarray of quadruple core samples from
71 primary and 12 recurrent AGCT was used for expression
analysis; three normal ovarian tissue samples were used for
controls. Clinicopathologic data of the patients and samples in
the TMA are presented in Table 1. The AGCT diagnoses were
verified by FOXL2 mutation and pathological review.
Immunohistochemical staining was performed as described
[17]. The primary antibody anti-human TRAIL (sc-1891,
Santa-Cruz) was used in a 1:50 dilution. Secondary antibody
only served as a negative control. The stained tissue sections
were examined using a Leica DM RXA microscope (Leica
microsystems GmbH, Wetzlar, Germany) ×20 and ×40 objec-
tives, and images were acquired using an Olympus DP70
camera and DP-capture software (Olympus, Center Valley,
PA, USA). Researchers (AF and UMH) independently ana-
lyzed the intensity of staining from four cores of each tumor in
relation to granulosa cells in the normal ovary. The expression
levels were correlated to clinical data as described previously
[1].
Patients and serum samples
We collected 141 serial serum samples from 83 AGCT patients
treated at the Department of Obstetrics and Gynecology,
Helsinki University Central Hospital during 2007–2012. The
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ethical committee of Helsinki University Central Hospital
(HUCH) and the National Supervisory Authority for Welfare
and Health in Finland approved the study, and all patients gave
their informed consent. The patient and sample details are
displayed in Table 2. The “with disease” (WD) samples were
drawn within a month before AGCT treatment, and the “dis-
ease-free” (DF) samples were drawn after a minimum of
3 months from the treatment, at the time of a clinical control
visit when the patient was disease-free. The samples were
classified according to patient’s menopausal status at sample
retrieval; “premenopausal” (PreMP) if the patient had one or
two ovaries, and menopause was not indicated in the medical
records (e.g., cessation of regular bleedings, presence of
menopausal symptoms, use of hormonal replacement thera-
py), and “postmenopausal” (PostMP) if both ovaries had been
removed independent of age, or the patient was postmeno-
pausal according to medical history. The median age was
41 years (range 26–54 years) for PreMP patients and 60 years
(range 44–86 years) for postMP patients.
Serum samples were prepared and stored at −80 °C until
analyzed for TRAIL with ELISA (R&D Systems, Minneapolis,
MN, USA) according to instructions and as previously described
[13, 29]. Sensitivity of the assay was 2.86 pg/ml, with the intra-
and inter-assay variabilites of 3.9 and 6.0 %, respectively. Blood
leukocyte counts and serum levels of estradiol (nmol/L), FSH,
LH (IU/L) were measured in the hospital routine with
Table 1 Clinicopathologic data of the patients (A) and samples (B) in the
TMA
A Patients N= 79 N (% of total)
Age at diagnosis, yearsa 50 (26–81)
Tumor stage at diagnosis
I 68 (86)
II 8 (10)
III 3 (4)
Initial treatment
Surgery only 62 (79)
Surg +Ch 12 (15)
Surg +Rad 2 (2)
Surg +Ch+Rad 3 (4)
Follow up time, yearsa 15.3 (0.7–38.6)
Recurrence
Yes 27 (34)
No 52 (66)
Survival
Alive 45 (57)
Dead of AGCT 19 (24)
Dead of other 15 (19)
B Tumor characteristics n (% of total)
Total n = 81 Primary 69 (86)
Recurrent 12 (14)
Subtype Sarcomatose
Differentiated
31 (38)
50 (62)
Nuclear atypia High 19 (23)
Low 62 (77)
Mitotic Index High 21 (26)
Low 60 (74)
Tumor size ≥10 cm 31 (38)
<10 cm 50 (62)
N number of patients, n number of samples, Surg surgery, Ch chemother-
apy, Rad radiotherapy
aMedian (range)
Table 2 Clinicopathologic data of the patients (A) and samples (B) in
the serum analysis
A Patients N= 83 N (% of total)
Age at diagnosis, yearsa 52 (19–81)
Tumor stage at diagnosis
I 77 (93)
II 5 (6)
III 1 (1)
Initial treatment
Surgery only 71 (86)
Surg +Ch 12 (14)
Follow up time, yearsa 8.4 (0.7–49.6)
Recurrence
Yes 21 (25)
No 62 (75)
Survival
Alive 81 (98)
Dead of AGCT 2 (2)
B Serum Samples Total N/n
Total 141/83
WD 39/30
Primary 17/17
Stage Ia 11/11
Stage Ic 6/6
Recurrent 22/13b
DF 102/77b
PreMPc 18 (13)
PostMPc 123 (87)
Tumor sizea 7.0 (2.0–30.0)
n number of samples, N number of patients, Surg surgery, Ch chemother-
apy, WDWith Disease, DF Disease-free, MPMenopausal
aMedian (range)
b Serial samples from multiple recurrences
cMP status at sample retrieval; “premenopausal” (PreMP) if the patient
had and one or two ovaries, and menopause was not indicated in the
medical records, and “postmenopausal” (PostMP) if the both ovaries
had been removed, or the patient was postmenopausal according to med-
ical history
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fluoroimmunometric assays (AutoDELFIA™, Wallac, Turku,
Finland). For analysis of continuous data, the values below de-
tection limit <0.1 (nmol/L for estradiol, IU/L for FSH and LH)
were set to 0.05 (nmol/L or IU/L).
Statistical analysis
TRAIL protein expression levels were correlated to clinical
parameters with contingency tabling and Fisher’s exact test.
The serum TRAIL data were tested to follow normal distribu-
tion with Shapiro-Wilk’s test and serial measurements were
analyzed with generalized linear model. Serum FSH, LH, and
estradiol levels and tumor size differed from normal distribu-
tion even after performing logarithmic transformation and
thus Mann–Whitney U test and Spearman’s rho were utilized.
For multiple regression, a generalized linear model and max-
imum likelihood ratio estimation were utilized for tumor size as
a continuous variable (with the most correlations in univariate
analysis), menopausal status, estradiol (nmol/L), and FHS and
LH (IU/L) levels, with soluble TRAIL (pg/ml) as the dependent
variable. p<0.05was considered significant. The analyses were
performed with JMP version 7.0.1 (SAS Institute Inc., Cary,
NC) software.
Results
TRAIL protein expression is reduced in large GCTs
We have previously shown that the TRAIL pathway plays an
essential role in granulosa cells [17]. To investigate the role of
TRAIL in malignant granulosa cells, we now analyzed the ex-
pression of TRAIL in AGCTs at both messenger RNA
(mRNA) and protein levels. In an analysis of 46 primary tumor
tissues, TRAILmRNAwas expressed at variable amounts, with
mean 1.6±1.2 arbitrary units, as compared to 0.08 arbitrary
units in normal granulosa-luteal cells (Supplemental Figure 1,
Supplemental Table 1). We found no correlations of TRAIL
mRNA levels to tumor size or other clinicopathological char-
acteristics (data not shown). In immunohistochemical analysis
of normal human ovary, TRAIL protein was expressed in theca
and granulosa cells, as well as in the ovarian stroma (Fig. 1a). In
AGCTs, TRAIL protein was expressed in 48 (59 %) of the
tumors at a level comparable to a normal granulosa cell, stain-
ing mostly diffusely in the tumor cells (Fig. 1b) and more
strongly in the tumor stroma (Fig. 1c). Thirty (37 %) AGCTs
exhibited low-intensity staining, and three (4 %) remained en-
tirely negative for TRAIL protein. Upon correlations between
clinical and immunohistochemical data, TRAIL protein expres-
sion was significantly lower in tumors over 10 cm in diameter
when compared to smaller tumors (p=0.04, OR 0.4 95% CI
0.2–0.97). TRAIL protein expression level was similar in pri-
mary (n=71) and recurrent (n=12) tumor samples, and the
expression levels did not correlate to tumor subtype, mitotic
index, nuclear atypia, tumor stage, or recurrence probability
(data not shown). TRAIL expression correlated positively to
the expression levels of the TRAIL receptors DR4 (p=0.006,
OR 11.3, 95% CI 1.4–91.9) and DR5 (p=0.02, OR 8.9, 95%
CI 1.1–73.1) previously analyzed in [21]. However, DR4 and
DR5 expressions did not correlate to tumor size (data not
shown). To further understand the reason for decreased
TRAIL protein expression in large AGCTs, we correlated the
TRAIL levels to factors linked to granulosa cell proliferation
and apoptosis, such as GATA4, Bcl2, and VEGF previously
analyzed in [21, 30–32]. Interestingly, we found that GATA4
and TRAIL levels positively correlated in the tumor tissue (OR
4.4, 95% CI 1.7–11.6, p=0.003). However, TRAIL expression
did not correlate with the expression of VEGF, VEGF recep-
tors, tumor microvessel density, or Bcl2 expression (data not
shown).
To investigate whether AGCT cells secrete soluble TRAIL,
we next analyzed TRAIL levels from the cell culture superna-
tants collected from 15 AGCT primary cell and KGN cell cul-
tures. We found that AGCT cells did not secrete measurable
amounts of soluble TRAIL into the supernatant (undetectable,
data not shown). However, TRAIL mRNA was expressed in
three primary AGCTcell preparations (mean=32.9±25.5 arbi-
trary units), at levels comparable to data previously obtained
from normal endothelial cells (mean=35.9±36 arbitrary units),
but at lower levels than that in peripheral blood mononuclear
cells (mean=63.4±48.7 arbitrary units) [25]. When studied
Fig. 1 Immunohistochemistry demonstrating TRAIL protein expression
in AGCTs. a TRAIL staining in a large dominant follicle (d) and a
primary follicle (p) of a normal human ovary. Positive staining is
visible in granulosa cells (arrows), thecal cells (asterisks), in endothelial
cells (small arrowheads), and in the stroma (big arrowheads). bAGCTof
the sarcomatose subtype showing diffuse TRAIL staining. c AGCTwith
TRAIL staining in the tumor islets (g) and in the tumor stroma
(arrowheads). d Secondary antibody only. Tumor cells and tumor
stroma (arrowhead) are negative. Original magnification ×20 in a, ×40
in b–d, scale bars 20 μm
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with immunofluorescence staining, the primary tumor cells
expressed FOXL2 protein as a marker for AGCT origin
(Fig. 2a–c) but remained negative for TRAIL expression
(Fig. 2d–h).
Circulating TRAIL levels are decreased in patients
with large AGCTs
To evaluate the dynamics of circulating TRAIL in AGCT pa-
tients, we next analyzed serum TRAIL concentrations from 141
serum samples, before (WD) and after (DF) tumor treatment.We
found that the tumor itself had little effect on circulating TRAIL
levels, as there was no significant difference in WD compared to
DF samples, (data not shown). However, soluble TRAIL levels
were significantly lower in patients with larger tumors of over
10 cm in diameter (mean 83.6, SD 29.2, pg/ml), than in patients
with tumors less than 10 cm in diameter (mean 122.1, SD
30.2 pg/ml; p=0.002) (Fig. 3a). Consistently, soluble TRAIL
levels inversely correlated to the tumor diameter as a continuous
variable (r=−0.4, p=0.01) (Fig. 3b). Upon correlations to other
clinical parameters, we found that TRAIL levels did not correlate
to the patient age at sample retrieval, body weight or height, or
blood leukocyte counts (data not shown).
Tumor size independently correlates to circulating TRAIL
levels
Circulating TRAIL levels have been shown to correlate inverse-
ly with patient’s estradiol levels [33], and we next analyzed
whether soluble TRAIL levels seen in large AGCTs associate
with the patient’s menopausal status, estradiol, and FSH and
LH levels. In patients with AGCT (WD), we found that circu-
lating TRAIL levels negatively associated with serum estradiol
levels (Spearman’s Rho −0.32, p = 0.05), whereas no
correlations were found to menopausal status, FSH, or LH
levels (data not shown).
We noted that larger tumors associated with PreMP status,
higher estradiol, and lower serum FSH and LH levels
(Table 3a). Menopausal status, estradiol, FSH and LH levels
correlated to each other, as expected (data not shown). In order to
verify which factor independently contributed to the decreased
TRAIL levels in AGCT patients, we next performed a multiple
regression analysis for tumor size, menopausal status, and estra-
diol, FSH, and LH levels with serum TRAIL as the dependent
variable (Table 3b). The analysis indicated that tumor size was
the only independent factor influencing circulating TRAIL levels
in AGCT patients (p=0.007).
Discussion
Despite improvements in the treatment modalities over the
past decades, ovarian cancer remains the leading cause of
death from gynecological cancers. AGCTs generally show
an indolent course of disease; however, recurrences occur in
30 % of the patients and the majority of these patients will die
of their disease [1, 34, 35]. Given the fact that current chemo-
therapeutics have only limited effect on AGCTs [5, 36], new,
targeted treatments are critically needed for patients with ad-
vanced AGCT.
TRAIL is a pro-apoptotic factor with promising anti-cancer
activity in a multitude of solid tumors [6–11]. Previous studies
have documented the expression of TRAIL in granulosa cells
[17] and TRAIL receptors in normal and malignant granulosa
cells [21], suggesting a role for the TRAIL/TRAIL receptor sys-
tem in regulating normal and malignant granulosa cell apoptosis.
Recombinant human TRAIL (rhTRAIL) induces apoptosis in
AGCT cells in vitro [17, 21]. Moreover, rhTRAIL was shown
to induce the activation of Caspase 3/7 and subsequent cell death
with lower concentrations in the primary AGCT tumor cells
when compared to the KGN cell line [21]. Preliminary clinical
data also suggests that AGCTs are susceptible to agonistic
TRAIL therapy also in human AGCT patients [11].
We herein find that AGCTs generally express TRAIL pro-
tein at levels comparable to normal granulosa cells. However,
tissue expression levels were decreased in large AGCTs.
TRAIL protein expression levels positively correlated with
those of transcription factor GATA4, which regulates apopto-
sis in AGCTs [21], and has been shown to be an important
delineator of AGCT prognosis [1, 30]. Moreover, GATA4 has
been shown to protect AGCT cells from TRAIL-induced apo-
ptosis in vitro [21]. Therefore, high expression of GATA4 in
AGCTs can be speculated to lead to resistance of TRAIL-
mediated apoptosis, and contributing to increased tumor growth.
However, we could not detect TRAIL protein in cultured primary
AGCT cells. Moreover, in immunohistochemistry, TRAIL pro-
tein expression was also detected in the tumor stroma, and
Fig. 2 Immunofluorescent staining of primary cultured AGCT cells.
First column; antigen staining visualized with GFP in green, second
column; DAPI showing the nuclei in blue, third column; merge. a–c
FOXL2 protein as a marker for AGCT cells localizes primarily in the
nuclei of tumor cells. d–f AGCT cells are predominantly negative for
TRAIL protein expression. A small amount of TRAIL staining is seen
around an apoptotic AGCT cell (arrow)
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TRAIL mRNAwas present at high levels in the primary AGCT
tumor samples, consisting also of tumor stroma. These findings
suggest that TRAIL protein is primarily produced by the tumor
stroma and/or infiltrating blood/immune cells. Thus, it can be
speculated that the decreased TRAIL production in the stroma
of large tumors contribute to AGCT progression via decreasing
Fig. 3 Serum TRAIL levels are
decreased in patients with large
AGCTs and correlate negatively
with tumor size. a S-TRAIL
levels in tumors less than 10 cm
and in tumors equal to or more
than 10 cm in diameter. b S-
TRAIL levels in correlation with
tumor size as the largest diameter.
r Spearman’s rho. An asterisk
indicates a significant difference
with p < 0.05
Table 3 Tumor size
independently correlates to serum
TRAIL levels. (A) Univariate
analyses to tumor size. (B)
Multiple regression with serum
TRAIL as the dependent variable
Tumor size (cm) (continuous)
p value
Tumor size
<10 cm
(categorical)
≥10 cm
p value
A Correlatons to tumor size as continuous and categorical value
PreMP mean ± SD;
14.7 ± 11.0
n = 3 n= 3
PostMP mean ± SD; 7.5 ± 5.0 0.01*a n = 25 n= 8 NSb
Estradiol
nmol/L
r= 0.41 0.01* median 0.07
range 0.01–0.33
median 0.21
range 0.04–0.93
NSc
FSH
IU/L
r=−0.64 <0.0001* median 15.3
range 0.05–101
median 1.2
range 0.05–50.1
0.006*c
LH
IU/L
r=−0.74 <0.0001* median 23.5
range 3–66.9
median 5.9
range 0.05–23.3
0.003*c
BMultiple regression of serum TRAIL as the dependent variable
Estimate 95%CI p value
Intercept 138.4 101.5–175.3 <0.0001*
Tumor size −3.0 −5.4– −0.7 0.001*
PreMP −15.7 −35.5–4.2 0.1
Estradiol −23.0 −80.5–34.6 0.4
FSH 0.4 −0.2–1.0 1.0
LH −0.9 −1.9–0.2 0.1
PreMP premenopausal, Postmp postmenopausal, SD standard deviation, CI confidence interval, IU international
units, L liter, NS not significant
r= Spearman’s rho, *indicates p < 0.05
aOne-way ANOVA
b Fisher’s exact test
cMann-Whitney U test
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apoptosis in the tumor cells expressing the TRAIL receptors
DR4 and DR5 [21] and, potentially, also via impairing tumor
defense mechanisms [37–39].
Circulating TRAIL levels were similar in patients with or
without AGCT; however, the levels were significantly de-
creased in AGCT patients with a large tumor mass, consistent
with our findings in the tumor tissue. AGCTs are known to
produce and release estrogens [24], and recent in vitro data
showed that estradiol downregulates the production of TRAIL
from leukocytes [25]. We found evidence that serum estradiol
levels correlated positively to tumor size, and also negatively
to circulating TRAIL levels in patients with AGCT. However,
in multivariable analysis, tumor size independently associated
with TRAIL levels, and therefore, it can be speculated that other
factors, such as the tumor stroma, also contribute to the levels of
circulating TRAIL. When designing optimal treatment strate-
gies for advanced AGCTs, the targeted treatment preferably
antagonizes with inherent pathogenetic factors, such as
GATA4, and further studies are warranted to evaluate whether
TRAIL agonists have such potential.
Utilizing a unique series of tumor tissue, cell culture, and
serum samples, we showed that large AGCTs are associated
with significantly decreased levels of tissue and serum
TRAIL. Our results support the role of TRAIL in AGCT tu-
mor progression, and encourage future studies on agonistic
TRAIL treatments for advanced or recurrent AGCT.
AGCT adult-type granulosa cell tumor, DF disease-free,
FSH follicle-stimulating hormone, LH luteinizing hormone,
PostMP postmenopausal, PreMP premenopausal, TMA tumor
tissue microarray, TRAIL TNF-related apoptosis-inducing li-
gand, rhTRAIL recombinant human TRAIL,WD with disease
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